Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib Plus Trastuzumab Deruxtecan in Advanced NSCLC With KRAS G12C Mutation
NCT07012031Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib and trastuzumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicities at 21 days and Overall Response Rate up to 5 years. Started Jun 2026; status: recruiting.
02
Drugs
sotorasibtrastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07012031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012031.